Two New Vaccine Candidates to Join Ebola Trial as Treatment Research Advances in DR Congo
GHealth News - The World Health Organization (WHO) has recommended the inclusion of two additional vaccine candidates in an ongoing clinical trial in the Democratic Republic of the Congo (DRC), marking a significant step forward in efforts to combat the current Bundibugyo virus disease outbreak.
The candidates, ChAdOx1, developed through a collaboration between the University of Oxford and the Serum Institute of India, and Moderna's mRNA-1469, are specifically designed to provide protection against Bundibugyo virus. They will become the first vaccines developed specifically for this Ebola virus species to undergo evaluation during an active outbreak.
The recommendation was issued by WHO's independent Technical Advisory Group on Candidate Vaccines Prioritization, following an assessme...